Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
26-29 March, 2025
Not Confirmed
Not Confirmed
27-29 March, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
26-29 March, 2025
Industry Trade Show
Not Confirmed
27-29 March, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
11 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/apnimed-appoints-kevin-r-lind-as-non-executive-chairman-of-the-board-of-directors-302397557.html
21 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/apnimed-to-participate-in-the-7th-annual-evercore-healthconx-conference-302312107.html
23 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/apnimed-strengthens-executive-team-and-board-of-directors-with-the-appointment-of-two-biopharmaceutical-industry-veterans-302284484.html
09 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/apnimed-announces-groundbreaking-survey-revealing-the-alarming-hidden-impact-of-obstructive-sleep-apnea-osa-302270750.html
26 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/apnimed-to-participate-in-the-4th-annual-needham-private-biotech-company-virtual-1x1-forum-302259214.html
19 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/apnimed-announces-early-completion-of-enrollment-in-phase-3-synairgy-study-of-ad109-the-first-potential-oral-treatment-addressing-the-neuromuscular-cause-of-obstructive-sleep-apnea-302252523.html
Details:
AD109 (aroxybutynin + atomoxetine) combines a novel NCE selective antimuscarinic. It is being evaluated in phase 3 clinial trials for treating obstructive sleep apnea.
Lead Product(s): Oxybutynin,Atomoxetin Hydrochloride
Therapeutic Area: Sleep Brand Name: AD109
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2024
Lead Product(s) : Oxybutynin,Atomoxetin Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Apnimed Completes Enrollment in Phase 3 Study of AD109 for Obstructive Sleep Apnea
Details : AD109 (aroxybutynin + atomoxetine) combines a novel NCE selective antimuscarinic. It is being evaluated in phase 3 clinial trials for treating obstructive sleep apnea.
Product Name : AD109
Product Type : Small molecule
Upfront Cash : Not Applicable
September 19, 2024
Details:
AD109 (aroxybutynin + atomoxetine) combines a novel NCE selective antimuscarinic, aroxybutynin, with a selective NRI, atomoxetine. It is being evaluated for the treatment of obstructive sleep apnea.
Lead Product(s): Oxybutynin,Atomoxetin Hydrochloride
Therapeutic Area: Sleep Brand Name: AD109
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2024
Lead Product(s) : Oxybutynin,Atomoxetin Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Apnimed Completes Enrollment in Phase 3 LunAIRo Study Of AD109
Details : AD109 (aroxybutynin + atomoxetine) combines a novel NCE selective antimuscarinic, aroxybutynin, with a selective NRI, atomoxetine. It is being evaluated for the treatment of obstructive sleep apnea.
Product Name : AD109
Product Type : Small molecule
Upfront Cash : Not Applicable
May 09, 2024
Details:
AD109 (aroxybutynin + atomoxetine) combines a novel NCE selective antimuscarinic, aroxybutynin, with a selective norepinephrine reuptake inhibitor (NRI), atomoxetine. It is being evaluated in phase 3 clinial trials for the treatment of Obstructive Sleep Apnea.
Lead Product(s): Aroxybutynin,Atomoxetin Hydrochloride
Therapeutic Area: Sleep Brand Name: AD109
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Lead Product(s) : Aroxybutynin,Atomoxetin Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AD109 (aroxybutynin + atomoxetine) combines a novel NCE selective antimuscarinic, aroxybutynin, with a selective norepinephrine reuptake inhibitor (NRI), atomoxetine. It is being evaluated in phase 3 clinial trials for the treatment of Obstructive Sleep ...
Product Name : AD109
Product Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2023
Details:
The joint venture will initially focus on accelerating the discovery, preclinical and clinical development of novel pharmacologic solutions designed to address the complex pathology of obstructive sleep apnea.
Lead Product(s): Undisclosed
Therapeutic Area: Sleep Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Small molecule
Sponsor: Shionogi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 31, 2023
Details : The joint venture will initially focus on accelerating the discovery, preclinical and clinical development of novel pharmacologic solutions designed to address the complex pathology of obstructive sleep apnea.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
October 31, 2023
Details:
AD109 (atomoxetine) has the potential to be the first nighttime oral pharmacologic treatment for people with OSA who are either intolerant of or refuse to use positive airway pressure (PAP) therapy.
Lead Product(s): Atomoxetin Hydrochloride,Aroxybutynin
Therapeutic Area: Sleep Brand Name: AD109
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AD109 (atomoxetine) has the potential to be the first nighttime oral pharmacologic treatment for people with OSA who are either intolerant of or refuse to use positive airway pressure (PAP) therapy.
Product Name : AD109
Product Type : Small molecule
Upfront Cash : Not Applicable
September 21, 2023
Details:
AD109 (atomoxetine) has the potential to be the first oral pharmacologic that both treats the underlying cause of OSA, airway obstruction at night, and improves daytime consequences of OSA such as fatigue.
Lead Product(s): Atomoxetin Hydrochloride,Aroxybutynin
Therapeutic Area: Sleep Brand Name: AD109
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Alpha Wave Ventures
Deal Size: $79.7 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 03, 2023
Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Alpha Wave Ventures
Deal Size : $79.7 million
Deal Type : Series C Financing
Details : AD109 (atomoxetine) has the potential to be the first oral pharmacologic that both treats the underlying cause of OSA, airway obstruction at night, and improves daytime consequences of OSA such as fatigue.
Product Name : AD109
Product Type : Small molecule
Upfront Cash : Undisclosed
January 03, 2023
Details:
AD109 (atomoxetine) is first oral pharmacologic that treats OSA airway obstruction at night. It is a first-in-class, novel, investigational combination dosed once daily at bedtime and is designed to treat OSA patients across a broad spectrum of disease severity.
Lead Product(s): Atomoxetin Hydrochloride,Aroxybutynin
Therapeutic Area: Sleep Brand Name: AD109
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AD109 (atomoxetine) is first oral pharmacologic that treats OSA airway obstruction at night. It is a first-in-class, novel, investigational combination dosed once daily at bedtime and is designed to treat OSA patients across a broad spectrum of disease s...
Product Name : AD109
Product Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2022
Details:
AD504 (Atomoxetine) showed a significant reduction of the Apnea Hypopnea Index (AHI) (from 18.2 [11.8 to 31.3] on placebo to 7.4 [5.4 to 16.1] events/h on AD504, p=0.024 and Hypoxic Burden (HB) from 46.3 [25.1 to 88.3] on placebo to 18.7 [14.9 to 43.5], p=0.003 on AD504.
Lead Product(s): Atomoxetin Hydrochloride,Trazodone Hydrochloride
Therapeutic Area: Sleep Brand Name: AD504
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Lead Product(s) : Atomoxetin Hydrochloride,Trazodone Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AD504 (Atomoxetine) showed a significant reduction of the Apnea Hypopnea Index (AHI) (from 18.2 [11.8 to 31.3] on placebo to 7.4 [5.4 to 16.1] events/h on AD504, p=0.024 and Hypoxic Burden (HB) from 46.3 [25.1 to 88.3] on placebo to 18.7 [14.9 to 43.5], ...
Product Name : AD504
Product Type : Small molecule
Upfront Cash : Not Applicable
June 02, 2022
Details:
Positive data on investigational oral pharmacologic treatment AD109 showed statistically significant and clinically meaningful benefits for patients with obstructive sleep apnea.
Lead Product(s): Atomoxetin Hydrochloride,Aroxybutynin
Therapeutic Area: Sleep Brand Name: AD109
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Apnimed Study APC-004 Phase 2 Data to be Presented at World Sleep 2022
Details : Positive data on investigational oral pharmacologic treatment AD109 showed statistically significant and clinically meaningful benefits for patients with obstructive sleep apnea.
Product Name : AD109
Product Type : Small molecule
Upfront Cash : Not Applicable
March 09, 2022
Details:
AD504 (atomoxetine plus trazodone) showed a strong trend in the reduction in apnea hypopnea index (AHI) from placebo, which was the study’s primary endpoint.
Lead Product(s): Atomoxetin Hydrochloride,Trazodone Hydrochloride
Therapeutic Area: Sleep Brand Name: AD504
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Lead Product(s) : Atomoxetin Hydrochloride,Trazodone Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AD504 (atomoxetine plus trazodone) showed a strong trend in the reduction in apnea hypopnea index (AHI) from placebo, which was the study’s primary endpoint.
Product Name : AD504
Product Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2021
ABOUT THIS PAGE